J.Safra Asset Management Corp Sells 144 Shares of Zoetis Inc. (NYSE:ZTS)

J.Safra Asset Management Corp lowered its position in Zoetis Inc. (NYSE:ZTS) by 32.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 302 shares of the company’s stock after selling 144 shares during the period. J.Safra Asset Management Corp’s holdings in Zoetis were worth $49,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Crew Capital Management Ltd. raised its position in shares of Zoetis by 7.6% in the 4th quarter. Crew Capital Management Ltd. now owns 6,064 shares of the company’s stock worth $988,000 after acquiring an additional 429 shares in the last quarter. Jag Capital Management LLC raised its position in shares of Zoetis by 1.6% in the 4th quarter. Jag Capital Management LLC now owns 14,153 shares of the company’s stock worth $2,306,000 after acquiring an additional 223 shares in the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Zoetis by 19.0% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 3,081 shares of the company’s stock worth $500,000 after acquiring an additional 491 shares in the last quarter. Bahl & Gaynor Inc. raised its position in shares of Zoetis by 2.9% in the 4th quarter. Bahl & Gaynor Inc. now owns 162,808 shares of the company’s stock worth $26,526,000 after acquiring an additional 4,522 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Zoetis by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,394,355 shares of the company’s stock valued at $553,042,000 after buying an additional 39,448 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Zoetis Stock Performance

NYSE ZTS opened at $166.96 on Thursday. The firm has a market cap of $74.76 billion, a price-to-earnings ratio of 30.52, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a 50-day moving average price of $166.57 and a 200-day moving average price of $176.99. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Barclays lifted their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.